Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effect on brain glucose metabolism
NCT01588418Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- Jul 2010
- Primary completion
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide in type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), sponsored by UT Health San Antonio. Started Jul 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT01588418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588418.